Eli Lilly inks $630M deal for Phase 1 MASH candidate
Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant announced a deal on Monday to license a Phase 1 ...

Apr 15, 2025 0
Apr 15, 2025 0
Apr 9, 2025 0
Apr 9, 2025 0
Apr 9, 2025 0
Apr 9, 2025 0
Or register with email
Feb 13, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 19, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.